Safety and Tolerability of Lactobacillus reuteri DSM 17938 and Effects on Biomarkers in Healthy Adults: Results from a Randomized Masked Trial

@inproceedings{Mangalat2012SafetyAT,
  title={Safety and Tolerability of Lactobacillus reuteri DSM 17938 and Effects on Biomarkers in Healthy Adults: Results from a Randomized Masked Trial},
  author={Nisha Mangalat and Yuying Liu and Nicole Y. Fatheree and Michael J. Ferris and Melissa R. Van Arsdall and Zhongxue Chen and Mohammad H Rahbar and Wallace A. Gleason and Johana Norori and Dat Q Tran and J Marc Rhoads},
  booktitle={PloS one},
  year={2012}
}
BACKGROUND There are few carefully-designed studies investigating the safety of individual probiotics approved under Investigational New Drug policies. OBJECTIVES The primary aim of this prospective, double-blind placebo-controlled trial was to investigate if daily treatment of adults with Lactobacillus reuteri DSM 17938 (LR) for 2 months is safe and well-tolerated. Our secondary aim was to determine if LR treatment has immune effects as determined by regulatory T cell percentages, expression… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Safety of Probiotics to Reduce Risk and Prevent or Treat Disease. Rockville, MD

  • S NSHempel, A Ruelaz, Z Wang, J Miles, M Suttorp
  • AHRQ Publication No. 11-E007. AHRQ Publication No…
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…